Filing Details

Accession Number:
0001209191-22-002529
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-07 18:04:58
Reporting Period:
2022-01-05
Accepted Time:
2022-01-07 18:04:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
914475 Neurocrine Biosciences Inc NBIX Biological Products, (No Disgnostic Substances) (2836) 330525145
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1567160 Kyle Gano 12780 El Camino Real
San Diego CA 92130
Chief Business Development Off No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-05 28,266 $8.66 133,250 No 4 M Direct
Common Stock Disposition 2022-01-05 28,266 $85.50 104,984 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option Disposition 2022-01-05 28,266 $8.66 28,266 $8.66
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2022-01-12 No 4 M Direct
Footnotes
  1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $83.11 to $87.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. Includes an aggregate of 216 shares purchased on February 26, 2021 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
  4. Option granted January 12, 2012 and vested monthly over four years.